Top

Indian Journal of Hematology and Blood Transfusion

18-12-2024 | Graft-Versus-Host Disease | Original Article

C-Reactive Protein/Albumin Ratio (CAR) Predicts Early Posttransplant Complications and Survival in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Authors: Şeyma Yıldız, Zeynep Arzu Yegin, Gonca Gül Gündem, Sema Yaşar, Seda Çiçekli, Zübeyde Nur Özkurt, Münci Yağcı

Published in: Indian Journal of Hematology and Blood Transfusion

Abstract

C reactive protein/albumin ratio (CAR) is considered as a predictor for prognosis in a variety of systemic disorders including malignancies. We aimed to investigate the potential impact of pretransplant CAR on transplant related complications and clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 430 alloHSCT recipients [median age: 44(18–72) years; male/female: 258/172] were included in this retrospective study. Median follow-up period was 761(1-5910) days. The study population was divided into two subgroups as low- (< 0.312) and high-CAR (≥ 0.312) [AUC: 0.61 (95%CI: 0.55–0.67); p < 0.001]. The probability of overall survival (OS) was significantly lower in CAR^high group (27.7% vs. 32.1%, p < 0.001). The frequency of posttransplant early complications including Cytomeglovirus reactivation (p = 0.04), sinusoidal obstruction syndrome (p = 0.042), sepsis (p = 0.004), nephrotoxicity (p = 0.011), dialysis requirement (p = 0.001) and acute GvHD (p = 0.026) were found to be significantly higher in CAR^high group. Pretransplant CAR was shown to have a significant impact on OS (p = 0.009) in multivariate analysis. Pretransplant CAR may be a feasible and cost effective marker to predict alloHSCT outcome for better management of early transplant related toxicity and complications.

Wang K, Jian X, Xu Z, Wang H (2023) Pre-transplant CRP-albumin ratio as a biomarker in patients receiving haploidentical allogeneic hematopoietic transplantation: Developing a novel DRCI-based nomogram. Front Immunol 14:1128982. https://doi.org/10.3389/fimmu.2023.1128982CrossRefPubMedPubMedCentral

Magenau J, Couriel DR (2013) Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how. Curr Oncol Rep 15(5):436–444. https://doi.org/10.1007/s11912-013-0340-6CrossRefPubMed

Dou L, Shi M, Song J, Niu X, Niu J, Wei S, Li D, Bai Y, Sun K (2022) The prognostic significance of C-reactive protein to albumin ratio in newly diagnosed acute myeloid leukaemia patients. Cancer Manag Res 14:303–316. https://doi.org/10.2147/CMAR.S343580CrossRefPubMedPubMedCentral

Cui X, Jia Z, Chen D, Xu C, Yang P (2020) The prognostic value of the C-reactive protein to albumin ratio in cancer: An updated meta-analysis. Med (Baltim) 99(14):e19165. https://doi.org/10.1097/MD.0000000000019165CrossRef

Yamamoto W, Fujii E, Matsumoto K, Yamamoto E, Aoki J, Tanaka M, Ishigatsubo Y, Kanamori H (2016) Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Int J Hematol 103(4):444–452. https://doi.org/10.1007/s12185-016-1941-2CrossRefPubMed

Soeters PB, Wolfe RR, Shenkin A, Hypoalbuminemia (2019) Pathogenesis and clinical significance. JPEN J Parenter Enter Nutr 43(2):181–193. https://doi.org/10.1002/jpen.1451CrossRef

Kwon JW, Jeon Y, Jung HY, Choi JY, Park SH, Kim CD, Kim YL, Hwang D, Yun WS, Kim HK, Huh S, Yoo ES, Won DI, Cho JH, Lim JH (2023) Pretransplant C-reactive protein-to-albumin ratio predicts mortality in kidney transplant recipients: a retrospective cohort study. Korean J Transpl 37(1):19–28. https://doi.org/10.4285/kjt.22.0047CrossRef

Jung J, Lee H, Heo JY, Chang MH, Lee E, Park WS, Park JH, Eom HS (2021) High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma. Sci Rep 11(1):2674. https://doi.org/10.1038/s41598-021-82087-6CrossRefPubMedPubMedCentral

Miyashita E, Konuma T, Kataoka J, Oiwa-Monna M, Mizusawa M, Isobe M, Kato S, Sato T, Takahashi S, Tojo A (2019) The prognostic impact of pretransplantation inflammatory and nutritional status in adult patients after myeloablative single cord blood transplantation. Biol Blood Marrow Transpl 25(5):981–988. https://doi.org/10.1016/j.bbmt.2019.01.006CrossRef

10.

Schaffrath J, Diederichs T, Unverzagt S, Wass M, Gläser U, Weber T, Binder M, Müller-Tidow C, Müller LP (2022) Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation. Ann Hematol 101(3):681–691. https://doi.org/10.1007/s00277-021-04736-0CrossRefPubMed

11.

Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T, Ma Y, Yang Y, He X, Zhao Y, Huang Y, Zhao H, Zhang L (2015) Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep 5:10481. https://doi.org/10.1038/srep10481CrossRefPubMedPubMedCentral

12.

Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M (2015) The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22(3):803–810. https://doi.org/10.1245/s10434-014-4048-0CrossRefPubMed

13.

Cao X, Cui J, Li Z, Zhao G (2021) Preoperative C-reactive protein/albumin ratio is a prognostic indicator for survival in surgically treated gastrointestinal stromal tumors: A retrospective cohort study. Cancer Manag Res 13:4155–4167. https://doi.org/10.2147/CMAR.S307873CrossRefPubMedPubMedCentral

14.

Park JE, Chung KS, Song JH, Kim SY, Kim EY, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Leem AY (2018) The C-reactive protein/albumin ratio as a predictor of mortality in critically ill patients. J Clin Med 7(10):333. https://doi.org/10.3390/jcm7100333CrossRefPubMedPubMedCentral

15.

Kawano N, Shimonodan H, Nagahiro Y, Yoshida S, Kuriyama T, Takigawa K, Tochigi T, Nakaike T, Makino S, Yamashita K, Marutsuka K, Ochiai H, Mori Y, Shimoda K, Ohshima K, Mashiba K, Kikuchi I (2023) The clinical impact of the ratio of C-reactive protein to albumin (CAR) in patients with acute- and lymphoma-type adult T-cell leukemia-lymphoma (ATL). J Clin Exp Hematop 63(2):73–82. https://doi.org/10.3960/jslrt.22039CrossRefPubMedPubMedCentral

16.

Jung J, Heo JY, Lee E, Lee H, Chang MH, Park JH, Eom HS (2023) Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma. Int J Hematol 117(2):216–224. https://doi.org/10.1007/s12185-022-03474-xCrossRefPubMed

17.

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15(12):1628–1633. https://doi.org/10.1016/j.bbmt.2009.07.004CrossRef

18.

Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M, ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98(12):1826–1835. https://doi.org/10.3324/haematol.2013.091025CrossRefPubMedPubMedCentral

19.

Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly J, Cordonnier C (2018) European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 73(12):3221-30. https://doi.org/10.1093/jac/dky286

20.

Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN (2017) European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19(8):e260-72. https://doi.org/10.1016/S1473-3099(19)30107-0

21.

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E (2016) Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl 51(7):906–912. https://doi.org/10.1038/bmt.2016.130CrossRef

22.

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. 21(3):389–401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001

23.

Kim KS, Kwon HM, Kim JH, Yang JW, Jun IG, Song JG, Hwang GS (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. C-reactive protein-to-albumin ratio is a predictor of 1-year mortality following liver transplantation. Anesth Pain Med (Seoul) 2022;17(4):420-8. https://doi.org/10.17085/apm.22176

24.

Senjo H, Onozawa M, Hidaka D, Yokoyama S, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Hashimoto D, Kondo T, Teshima T (2022) High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia. Sci Rep 12(1):8885. https://doi.org/10.1038/s41598-022-12813-1CrossRefPubMedPubMedCentral

25.

Tang HN, Pan BH, Wang L, Zhu HY, Fan L, Xu W, Li JY (2021) C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases. Transl Oncol 14(4):101035. https://doi.org/10.1016/j.tranon.2021.101035CrossRefPubMedPubMedCentral

26.

Di QS, Xu T, Song Y, Zuo ZG, Cao FJ, Yu XJ, Tang JY, Zhang W, Li C, Wan GX, Cai XJ (2020) High C-reactive protein to albumin ratio predicts inferior clinical outcomes in extranodal natural killer T-cell lymphoma. Dose Response 18(2):1559325820917824. https://doi.org/10.1177/1559325820917824CrossRefPubMedPubMedCentral

27.

Lucijanic M, Galusic D, Krecak I, Sedinic M, Soric E, Holik H, Perisa V, Moric Peric M, Zekanovic I, Stoos-Veic T, Kusec R (2020) C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis. Leuk Lymphoma 61(12):2969–2974. https://doi.org/10.1080/10428194.2020.1789627CrossRefPubMed

28.

Brauer D, Backhaus D, Pointner R, Vucinic V, Niederwieser D, Platzbecker U, Schwind S, Jentzsch M (2021) Nutritional status at diagnosis and pre-transplant weight loss impact outcomes of acute myeloid leukemia patients following allogeneic stem cell transplantation. Hemasphere 5(3):e532. https://doi.org/10.1097/HS9.0000000000000532CrossRefPubMedPubMedCentral

29.

Wu P, Liang W, Chen X, Chen L, Yang X, Yan Z, Wang W (2019) Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis. Med (Baltim) 98(8):e14474. https://doi.org/10.1097/MD.0000000000014474CrossRef

30.

Tvedt THA, Ersvaer E, Tveita AA, Bruserud Ø (2017) Interleukin-6 in allogeneic stem cell transplantation: Its possible importance for immunoregulation and as a therapeutic target. Front Immunol 8:667. https://doi.org/10.3389/fimmu.2017.00667CrossRefPubMedPubMedCentral

31.

Chung H, Jang JE, Kim SJ, Kim JS, Min YH, Cheong JW (2020) Serum albumin and C-reactive protein as significant predictors of non-relapse mortality in lower gastrointestinal graft-versus-host disease. Ann Hematol 99(5):1111–1119. https://doi.org/10.1007/s00277-020-04015-4CrossRefPubMed

32.

Minculescu L, Kornblit BT, Friis LS, Schiødt I, Petersen SL, Andersen NS, Sengeloev H (2018) C-reactive protein levels at diagnosis of acute graft-versus-host disease predict steroid-refractory disease, treatment-related mortality, and overall survival after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 24(3):600–607. https://doi.org/10.1016/j.bbmt.2017.10.025CrossRef

33.

Rezvani AR, Storer BE, Storb RF, Mielcarek M, Maloney DG, Sandmaier BM, Martin PJ, McDonald GB (2011) Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl 17(11):1594–1601. https://doi.org/10.1016/j.bbmt.2011.07.021CrossRef

34.

Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Escolar G, Eissner G, Holler E, Carreras E (2009) The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transpl 15(5):537–546. https://doi.org/10.1016/j.bbmt.2009.01.013CrossRef

35.

Liu B, Lv D (2023) Prognostic value of C-reactive protein to albumin ratio for mortality in acute kidney injury. BMC Nephrol 24(1):44. https://doi.org/10.1186/s12882-023-03090-9CrossRefPubMedPubMedCentral

36.

Kawai Y, Masutani K, Torisu K, Katafuchi R, Tanaka S, Tsuchimoto A, Mitsuiki K, Tsuruya K, Kitazono T (2018) Association between serum albumin level and incidence of end-stage renal disease in patients with Immunoglobulin A nephropathy: A possible role of albumin as an antioxidant agent. PLoS ONE 13(5):e0196655. https://doi.org/10.1371/journal.pone.0196655PMID: 29795559; PMCID: PMC5968404CrossRefPubMedPubMedCentral

37.

Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19(4):972–978. https://doi.org/10.1161/01.atv.19.4.972CrossRefPubMed

Title: C-Reactive Protein/Albumin Ratio (CAR) Predicts Early Posttransplant Complications and Survival in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
Authors: Şeyma Yıldız
Zeynep Arzu Yegin
Gonca Gül Gündem
Sema Yaşar
Seda Çiçekli
Zübeyde Nur Özkurt
Münci Yağcı
Publication date: 18-12-2024
Publisher: Springer India
Keywords: Graft-Versus-Host Disease
Graft-Versus-Host Disease
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Septicemia
Septicemia
Conditioning
Published in: Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-024-01942-4

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote webinar | Spotlight on advances in lupus

Springer Medicine

C-Reactive Protein/Albumin Ratio (CAR) Predicts Early Posttransplant Complications and Survival in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Abstract

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote webinar | Spotlight on advances in lupus

Springer Medicine

Abstract

Please log in to get access to this content

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma